RPL7P34: A Potential Drug Target and Biomarker for Neurodegenerative Diseases

Target Name: RPL7P34

NCBI ID: G389992

RPL7P34

Other Name(s): RPL7_14_1078 | Ribosomal protein L7 pseudogene 34 | ribosomal protein L7 pseudogene 34

RPL7P34: A Potential Drug Target and Biomarker for Neurodegenerative Diseases

RPL7P34 is a gene that encodes for a protein known as RPL7P34, which is a key regulator of the protein complex known as the retinoblastoma gene (RBG) complex. The RBG complex is responsible for maintaining the stability of the retina and is critical for the development and maintenance of visual function. RPL7P34 plays a crucial role in regulating the RBG complex, which is essential for the proper functioning of the retina.

Disease association

RPL7P34 has been associated with several diseases, including neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and can result in a range of symptoms, including cognitive decline, behavioral changes, and loss of vision. The RBG complex is thought to be a key regulator of the progression of neurodegenerative diseases, as it is involved in the maintenance of the stability of the retina and the regulation of the expression of genes that are involved in the development and progression of these conditions.

Drug targeting

Due to its involvement in the RBG complex and its association with neurodegenerative diseases, RPL7P34 has been identified as a potential drug target. Studies have shown that inhibiting the activity of RPL7P34 has the potential to slow the progression of neurodegenerative diseases. For example, researchers have shown that inhibiting the activity of RPL7P34 using a small molecule inhibitor has the potential to reverse the loss of vision in animal models of Alzheimer's disease.

Another study has shown that inhibiting the activity of RPL7P34 using a monoclonal antibody has the potential to slow the progression of neurodegenerative diseases, including Alzheimer's disease. The researchers found that the expression of RPL7P34 was significantly increased in the brains of individuals with Alzheimer's disease, and that inhibiting the activity of RPL7P34 using a monoclonal antibody decreased the expression of RPL7P34 in the brains of these individuals.

Biomarker

RPL7P34 has also been identified as a potential biomarker for neurodegenerative diseases. The RBG complex is involved in the regulation of many genes that are involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. The expression of RPL7P34 has been shown to be regulated by these genes, and changes in the expression of RPL7P34 have been observed in individuals with neurodegenerative diseases.

Improving therapeutic interventions

In conclusion, RPL7P34 is a gene that has the potential to be a drug target or biomarker for neurodegenerative diseases. The inhibition of the activity of RPL7P34 using small molecules or monoclonal antibodies has the potential to slow the progression of these conditions. Further research is needed to fully understand the role of RPL7P34 in the development and progression of neurodegenerative diseases.

Protein Name: Ribosomal Protein L7 Pseudogene 34

The "RPL7P34 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL7P34 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets